CryoPort, Inc. (CYRX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, CYRX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross."A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving averages being the ...

New SC vapor shipper series improves reliability through extended hold times and patented impact-absorbing and Vapor Shield Technology NASHVILLE, Tenn., July 8, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced the launch of MVE Biological Solutions' new vapor shippers, the SC 4/2V and SC 4/3V, offering medical and animal health professionals, laboratories, researchers, hospitals and clinics, pharmaceut ...

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Summary: CryoPort, Inc. (CYRX) - CYRX currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for potential outperformance in the market [3] - Over the past week, CYRX shares increased by 16.33%, significantly outperforming the Zacks Transportation - Services industry, which rose by 1.78% [5] - In a longer timeframe, CYRX shares have risen by 46.46% over the past three months and 22.36% over the past year, while the S&P 500 only increased by 16.66% and 14.76%, respectively [6] - The average 20-day trading volume for CYRX is 562,557 shares, indicating a bullish trend as the stock is rising with above-average volume [7] Earnings Outlook - In the past two months, three earnings estimates for CYRX have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from -$0.84 to -$0.82 [9] - For the next fiscal year, three estimates have also moved upwards, reflecting positive sentiment regarding the company's earnings potential [9] Conclusion - Given the strong momentum indicators and positive earnings outlook, CYRX is identified as a promising investment opportunity with a Momentum Score of A and a Zacks Rank of 2 (Buy) [11]

Core Viewpoint - CryoPort, Inc. (CYRX) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of a company's shares, leading to significant buying or selling actions that affect stock prices [4]. Recent Performance and Outlook - For the fiscal year ending December 2025, CryoPort is expected to earn -$0.82 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 25.7% over the past three months [8]. - The upgrade to Zacks Rank 2 places CryoPort in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The system maintains a balanced distribution of ratings, ensuring that only the top 20% of stocks receive a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10].

Core Insights - Cryoport, Inc. has completed the divestiture of its specialty courier business, CRYOPDP, to DHL Group for approximately $200 million in cash [1][4] - A strategic partnership has been established between Cryoport and DHL to enhance supply chain services in the global life sciences and healthcare sector [2][3] Financial Impact - The divestiture provides a significant capital infusion, improving Cryoport's growth trajectory and positioning the company for sustainable, long-term profitability [4] Strategic Focus - The partnership with DHL is expected to enhance Cryoport's capabilities in the Asia Pacific and EMEA regions, allowing for targeted services in response to market demand [3] - Cryoport aims to intensify its focus on advancing its Life Science Services platform, particularly in the regenerative medicine market [3] Company Overview - Cryoport is a leader in temperature-controlled supply chain solutions for the life sciences, emphasizing regenerative medicine [5] - The company offers a comprehensive suite of services designed to minimize risk and maximize reliability across the temperature-controlled supply chain [5]

Core Viewpoint - CryoPort, Inc. (CYRX) has seen a 7.3% increase in share price over the past four weeks, closing at $6.03, with a potential upside indicated by Wall Street analysts' mean price target of $10.94, suggesting an 81.4% increase [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $3.05, indicating variability among analysts; the lowest estimate is $6.50 (7.8% increase), while the highest is $15 (148.8% increase) [2][9]. - Analysts' consensus on price targets is often questioned, as they may not accurately reflect future stock prices; empirical research suggests that price targets can mislead investors [3][7]. - Despite skepticism around price targets, a low standard deviation among estimates indicates strong agreement among analysts regarding the stock's price direction [9][10]. Earnings Estimates and Market Sentiment - Analysts are optimistic about CYRX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlate with stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has risen by 20.8% over the past month, with four estimates increasing and no negative revisions [12]. - CYRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [13].

Group 1 - CryoPort, Inc. (CYRX) shares have increased by 22.5% in the past four weeks, closing at $7.07, with a mean price target of $10.94 indicating a potential upside of 54.7% [1] - The average price targets from analysts range from a low of $6.50 to a high of $15, with a standard deviation of $3.05, suggesting variability in estimates [2] - Analysts are optimistic about CYRX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for CYRX's current year earnings has increased by 23.2% over the past month, with four estimates revised upward and no negative revisions [12] - CYRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While price targets may not be entirely reliable, the direction they imply can serve as a useful guide for potential price movements [10][13]

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This section covers the company's unaudited financial statements, management's discussion, market risk, and internal controls [Financial Statements](index=4&type=section&id=ITEM%201.%20Financial%20Statements) This section presents Cryoport's unaudited condensed consolidated financial statements, including CRYOPDP reclassification and reduced net loss [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet shows total assets at **$699.8 million**, reflecting CRYOPDP reclassification, stable liabilities, and slight equity decrease Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 (unaudited, in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $36,102 | $34,137 | | Total current assets | $411,276 | $341,572 | | Current assets held for sale | $108,090 | $36,251 | | Total assets | $699,844 | $703,493 | | **Liabilities & Equity** | | | | Total current liabilities | $74,030 | $64,563 | | Total liabilities | $301,033 | $301,595 | | Total stockholders' equity | $398,811 | $401,898 | | Total liabilities and stockholders' equity | $699,844 | $703,493 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Total revenue from continuing operations increased **10.1%** to **$41.0 million**, with improved gross margin and reduced net loss Q1 2025 vs Q1 2024 Statement of Operations (in thousands, except per share data) | Metric | Q1 2025 (in thousands) | Q1 2024 (in thousands) | | :--- | :--- | :--- | | Total revenue | $41,040 | $37,291 | | Gross margin | $18,641 | $15,065 | | Loss from operations | $(9,484) | $(17,508) | | Loss from continuing operations | $(9,028) | $(15,035) | | Net loss | $(11,981) | $(18,895) | | Net loss attributable to common stockholders | $(13,981) | $(20,895) | | Net loss per share - basic and diluted | $(0.28) | $(0.43) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities was **$4.3 million**, with investing activities providing **$5.9 million**, leading to a net cash increase Cash Flow Summary (in thousands) | Activity | Three Months Ended March 31, 2025 (in thousands) | Three Months Ended March 31, 2024 (in thousands) | | :--- | :--- | :--- | | Net cash used in operating activities | $(4,342) | $(3,265) | | Net cash provided by investing activities | $5,922 | $6,445 | | Net cash (used in) provided by financing activities | $(189) | $512 | | Net change in cash and cash equivalents | $2,072 | $3,317 | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) These notes detail accounting policies, the **$195 million** CRYOPDP divestiture, revenue disaggregation, and segment performance - On March 31, 2025, Cryoport entered a definitive agreement to divest its CRYOPDP specialty courier business to DHL for a total enterprise value of **$195 million**. The transaction is expected to close in Q2 or Q3 2025[23](index=23&type=chunk)[48](index=48&type=chunk) - The CRYOPDP business has been classified as discontinued operations. Its assets and liabilities are now presented as 'held for sale' on the balance sheet, and its results are reported separately from continuing operations[24](index=24&type=chunk)[26](index=26&type=chunk)[49](index=49&type=chunk) Revenue from Continuing Operations by Geography (in thousands) | Region | Q1 2025 (in thousands) | Q1 2024 (in thousands) | | :--- | :--- | :--- | | Americas | $32,195 | $26,690 | | EMEA | $5,580 | $7,400 | | APAC | $3,265 | $3,201 | | **Total** | **$41,040** | **$37,291** | Segment Adjusted EBITDA (in thousands) | Segment | Q1 2025 (in thousands) | Q1 2024 (in thousands) | | :--- | :--- | :--- | | Life Sciences Services | $(2,484) | $(4,940) | | Life Sciences Products | $3,510 | $2,123 | | **Total Segment Adjusted EBITDA** | **$1,026** | **$(2,817)** | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=37&type=section&id=ITEM%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2025 financial performance, highlighting revenue growth, improved gross margin, and the strategic CRYOPDP divestiture [Overview](index=39&type=section&id=MD%26A%20Overview) Cryoport, a life sciences supply chain leader, supported **711 clinical trials** and **19 commercial therapies**, strategically divesting CRYOPDP - As of March 31, 2025, Cryoport supported **711 clinical trials** globally, an increase from 675 at March 31, 2024. Of these, **79 were in Phase 3**[116](index=116&type=chunk)[122](index=122&type=chunk) - The company supports **19 commercial therapies**, anticipating that approved therapies will become significant revenue drivers[116](index=116&type=chunk) - The divestiture of CRYOPDP and strategic partnership with DHL is expected to enhance the company's ability to develop its business, particularly in the EMEA and APAC regions[118](index=118&type=chunk) [Results of Operations](index=41&type=section&id=Results%20of%20Operations) Total revenue from continuing operations grew **10.1%** to **$41.0 million**, driven by Life Sciences Services growth and improved gross margin Revenue from Continuing Operations by Segment (in thousands) | Segment | Q1 2025 (in thousands) | Q1 2024 (in thousands) | $ Change (in thousands) | % Change | | :--- | :--- | :--- | :--- | :--- | | Life Sciences Services | $22,865 | $19,485 | $3,380 | 17.3% | | Life Sciences Products | $18,175 | $17,806 | $369 | 2.1% | | **Total revenue** | **$41,040** | **$37,291** | **$3,749** | **10.1%** | - The increase in Life Sciences Services revenue was driven by year-over-year growth in BioStorage/BioServices (**22.8%**) and Commercial Cell & Gene therapy revenue (**32.9%**)[122](index=122&type=chunk) - Overall gross margin improved to **45.4%** in Q1 2025 from 40.4% in Q1 2024[124](index=124&type=chunk) - SG&A expenses decreased by **$3.6 million** (**13.0%**), mainly due to a **$5.2 million** decrease in contingent consideration, offset by **$2.4 million** in costs related to the CRYOPDP divestiture[128](index=128&type=chunk) [Non-GAAP Financial Measures](index=44&type=section&id=Non-GAAP%20Financial%20Measures) Adjusted EBITDA from continuing operations improved to a loss of **$2.8 million**, with a minor negative FX impact on revenue Adjusted EBITDA Reconciliation (in thousands) | Line Item | Q1 2025 (in thousands) | Q1 2024 (in thousands) | | :--- | :--- | :--- | | GAAP loss from continuing operations | $(9,028) | $(15,035) | | **Adjusted EBITDA from continuing operations** | **$(2,819)** | **$(6,657)** | - For the three months ended March 31, 2025, revenue would have been **$0.3 million** higher on a constant currency basis, representing a **-0.7% FX impact**[143](index=143&type=chunk)[146](index=146&type=chunk) [Liquidity and Capital Resources](index=48&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains strong liquidity with **$36.1 million** in cash and **$207.9 million** in short-term investments, sufficient for future operations - As of March 31, 2025, the company had cash and cash equivalents of **$36.1 million** and short-term investments of **$207.9 million**[148](index=148&type=chunk) - Net cash used in operating activities for Q1 2025 was **$4.3 million**[150](index=150&type=chunk)[151](index=151&type=chunk) - As of March 31, 2025, approximately **$73.9 million** of repurchase authorization remains available under the company's repurchase programs[89](index=89&type=chunk)[158](index=158&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=50&type=section&id=ITEM%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section details the company's market risk exposure, primarily from interest rate and foreign currency fluctuations - The company's primary market risks are interest rate changes affecting its debt and investment portfolio, and foreign currency fluctuations from international operations[160](index=160&type=chunk) - A hypothetical 10% adverse change in foreign exchange rates would result in a **$2.3 million** decline in the value of foreign-denominated cash and a **$3.5 million** loss related to long-term intercompany loans[163](index=163&type=chunk)[164](index=164&type=chunk) [Controls and Procedures](index=50&type=section&id=ITEM%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective, with no material changes to internal controls during the quarter - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of March 31, 2025[166](index=166&type=chunk) - No material changes to internal control over financial reporting occurred during the quarter ended March 31, 2025[169](index=169&type=chunk) [PART II. OTHER INFORMATION](index=52&type=section&id=PART%20II.%20OTHER%20INFORMATION) This section details legal proceedings, risk factors, equity security sales, and lists filed exhibits [Legal Proceedings](index=52&type=section&id=ITEM%201.%20Legal%20Proceedings) The company is not aware of any legal proceedings materially affecting its business or financial condition - The company is not aware of any legal proceedings that would have a material adverse effect on its business[170](index=170&type=chunk) [Risk Factors](index=52&type=section&id=ITEM%201A.%20Risk%20Factors) This section refers readers to detailed risk factors in the company's latest Annual Report on Form 10-K - For a detailed discussion of risk factors, the report refers to the company's 2024 Annual Report on Form 10-K[171](index=171&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=52&type=section&id=ITEM%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales or issuer purchases of equity securities occurred during the quarter - No unregistered sales of equity securities occurred during the quarter ended March 31, 2025[172](index=172&type=chunk) - No issuer purchases of equity securities were made during the quarter[173](index=173&type=chunk) [Exhibits](index=53&type=section&id=ITEM%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including the CRYOPDP divestiture agreement and certifications

Financial Performance - CryoPort, Inc. reported a quarterly loss of $0.22 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.23, and an improvement from a loss of $0.43 per share a year ago, indicating an earnings surprise of 4.35% [1] - The company posted revenues of $41.04 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.91%, but down from $54.59 million in the same quarter last year [2] - Over the last four quarters, CryoPort has exceeded consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance and Outlook - CryoPort shares have declined approximately 28.8% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.22 on revenues of $41.95 million, and for the current fiscal year, it is -$0.84 on revenues of $168.12 million [7] Industry Context - The Transportation - Services industry, to which CryoPort belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact CryoPort's stock performance [5][6]

Financial Data and Key Metrics Changes - Cryoport reported $41 million in revenue from continuing operations for Q1 2025, representing a 10% year-over-year growth and contributing to significant adjusted EBITDA improvement [10] - The company confirmed its revenue guidance for fiscal year 2025 in the range of $165 million to $172 million, indicating a 7.5% growth compared to fiscal year 2024 [13] Business Line Data and Key Metrics Changes - Life sciences services revenue increased by 17% year-over-year, driven by a 33% growth in support for commercial cell and gene therapies [10] - Life sciences services now account for 56% of total revenue, reflecting the increasing development and commercialization of cell and gene therapies [10] - The life sciences products business showed a 2% year-over-year growth, indicating demand stabilization [12] Market Data and Key Metrics Changes - Cryoport supported 19 commercial therapies and 711 clinical trials as of March 31, representing approximately 70% of cell and gene therapy trials [11] - The company anticipates up to 17 additional application filings and four therapy approvals for the remainder of 2025, indicating a robust pipeline [11] Company Strategy and Development Direction - The strategic partnership with DHL, involving the sale of Cryo PDP for an enterprise value of $195 million, is expected to enhance Cryoport's positioning in Asia Pacific and EMEA [12][13] - The partnership aims to leverage DHL's global scale and capabilities, allowing Cryoport to sharpen its focus on core life sciences service offerings in the regenerative medicine space [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth forecast despite potential tariff impacts, stating that they have taken steps to diversify the supply chain [14][15] - The company does not expect tariffs to significantly impact core support for clinical trials or commercial therapies [15] - Management remains optimistic about the commercial revenue ramp-up and the maturation of commercial therapies [44] Other Important Information - The company reported a significant increase in service gross margins year-over-year, with expectations for continued margin improvements [34] - The onboarding process for EntegraCell is progressing smoothly, with multiple commercial contracts already in place [65] Q&A Session Summary Question: Update on the launch of Entegrisel and client adoption - Management sees the market positively, with commercial revenue continuing to ramp and growth in clinical trials [20] Question: Contingent consideration impact on adjusted EBITDA - Management clarified that contingent consideration was backed out, and adjusted EBITDA improved significantly compared to Q1 of the previous year [29] Question: Response to potential tariffs and macro environment - Management indicated no significant tariff impact on cell and gene therapy, with continued commercial revenue growth [41][42] Question: Supply chain initiatives and margin improvements - Management stated that while they cannot quantify the impact of supply chain initiatives on margins, they expect strong gross margins to continue [54] Question: Impact of the new FDA director on therapy modalities - Management expressed optimism about the new FDA director's qualifications and the continued interest in cell and gene therapy [56] Question: Demand for new product launches - Management reported positive reception and ongoing adoption for new products, with expectations for substantial contributions in the future [62]